STAA STAAR Surgical Company

Net Sales Up 10% to $88.6 Million Driven by Growth in All Regions

Americas Up 14%, EMEA Up 12% and APAC Up 9%

Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity

The end of the paragraph after bullets in the "Outlook" section of release should read: APAC sales growth of 5% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%) and all other APAC countries approximately 10-20% growth (prior outlook was flat). (Instead of: APAC sales growth of 4% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030604379/en/

The updated release reads: 

STAAR SURGICAL REPORTS THIRD QUARTER 2024 RESULTS

Net Sales Up 10% to $88.6 Million Driven by Growth in All Regions

Americas Up 14%, EMEA Up 12% and APAC Up 9%

Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 27, 2024.

Third Quarter 2024 Overview

• Net sales of $88.6 million, up 10% from prior year quarter
• ICL sales of $89.1 million, up 10% from prior year quarter
• Gross margin of 77.3% as compared to 79.2% year ago
• Net income of $10.0 million or $0.20 per share, up from $4.8 million or $0.10 per share year ago
• Adjusted EBITDA of $16.2 million or $0.33 per share as compared to $16.5 million or $0.33 per share year ago
• $236.0 million of cash, cash equivalents and investments available for sale as of September 27, 2024

“In the third quarter, we achieved double-digit sales growth against a macroeconomic environment that softened in the second half of the quarter, particularly in China,” said Tom Frinzi, President and CEO of STAAR Surgical. “STAAR is well positioned to navigate through the current market dynamics, which we believe are transitory. Looking ahead, we are encouraged by the recent shift in fiscal policy and announced stimulus in China and will continue to closely monitor the potential impact on our near to midterm growth outlook.”

Mr. Frinzi concluded, “Our focus on customer engagement and market expansion continues to yield solid results, helping drive industry-leading growth and market share gains. As our surgeon customers perform more EVO procedures, they are increasingly using our technology for moderate myopia, which underscores EVO ICL as the treatment choice for -6D and above and expands our total addressable market.”

Third Quarter 2024 Financial Results

Net sales were $88.6 million for the third quarter of 2024, up 10% from $80.3 million reported in the prior year quarter. This sales increase was driven by ICL sales growth of $8.0 million, up 10%, and unit growth of 6% from the prior year period. Other Product sales declined $0.2 million from the prior year period. Changes in currency, primarily the Japanese Yen, negatively impacted reported total net sales by $0.3 million for the third quarter of 2024.

Gross profit margin for the third quarter of 2024 was 77.3% of net sales as compared to the prior year quarter of 79.2% of net sales. Gross margin in the third quarter was lower primarily due to reduced unit production that resulted in less absorption of fixed overhead.

Operating expenses for the third quarter of 2024 were $62.8 million, up from the prior year quarter of $57.3 million. General and administrative expenses were $21.7 million, up from $19.3 million in the prior year quarter, driven primarily by increased facility costs and compensation-related expenses. Selling and marketing expenses were $26.6 million – consistent with the prior year quarter. Research and development expenses were $14.5 million, up from the prior year quarter of $11.5 million, primarily due to purchases of in-process research and development, as well as compensation-related expenses, which were partially offset by lower clinical trial costs.

Operating income for the third quarter of 2024 was $5.7 million or 6.4% of net sales as compared to operating income of $6.3 million or 7.8% of net sales for the third quarter of 2023.

Net income for the third quarter of 2024 was $10.0 million or $0.20 income per share, up from $4.8 million or $0.10 income per share for the prior year quarter. The increase in net income was primarily attributable to a gain on foreign currency transactions.

As of September 27, 2024, cash, cash equivalents and investments available for sale totaled $236.0 million, up from $232.4 million on December 29, 2023.

Outlook

The Company maintained its prior outlook for fiscal year 2024 net sales and Adjusted EBITDA.

• Net sales of $340 million to $345 million.
• Adjusted EBITDA of approximately $42 million and Adjusted EBITDA per diluted share of approximately $0.80.

The outlook above contemplates EVO ICL sales growth of 17% in the Americas (prior outlook was 15%) including 20% in the U.S. (prior outlook was 25%); EMEA sales growth of 10% (prior outlook was 6%); and APAC sales growth of 5% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%) and all other APAC countries approximately 10-20% growth (prior outlook was flat).

Earnings Webcast

The Company will host an earnings webcast today, Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the webcast please use the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmU0YbKB.

The live webcast, earnings webcast presentation and an archived version of the webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

Use of Non-GAAP Financial Measures

To supplement the Company’s financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), this press release and the accompanying tables include certain non-GAAP financial measures, including Adjusted EBITDA. Management uses these non-GAAP financial measures in its evaluation of Company operating performance and believes investors will find them useful in evaluating the Company’s operating performance, including cash flow generation, and in analyzing period-to-period financial performance of core business operations and underlying business trends. Non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

EBITDA is a non-GAAP financial measure, which is calculated by adding interest income and expense, net; provision for income taxes; and depreciation and amortization to net income. In calculating Adjusted EBITDA and Adjusted EBITDA per diluted share, the Company further adjusts for stock-based compensation expense. As stock-based compensation is a non-cash expense that can vary significantly based on the timing, size and nature of awards granted, the Company believes that the exclusion of stock-based compensation expense can assist investors in comparisons of Company operating results with other peer companies because (i) the amount of such expense in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expense can vary significantly between periods as a result of the timing of grants of new stock-based awards, including inducement grants in connection with hiring. Additionally, the Company believes that excluding stock-based compensation from Adjusted EBITDA and Adjusted EBITDA per diluted share assists management and investors in making meaningful comparisons between the Company’s operating performance and the operating performance of other companies that may use different forms of employee compensation or different valuation methodologies for their stock-based compensation. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods. Investors should also note that such expenses will recur in the future.

The Company also presents certain financial information on a constant currency basis, which is intended to exclude the effects of foreign currency fluctuations. The Company conducts a significant part of its activities outside the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and euros. The exchange rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on the Company’s results when reported in U.S. dollars. In order to compare the Company's performance from period to period without the effect of currency, the Company will apply the same average exchange rate applicable in the prior period, or the “constant currency” rate to sales or expenses in the current period as well.

In the tables provided below, the Company has included a reconciliation of Adjusted EBITDA and Adjusted EBITDA per diluted share to net income and net income per diluted share, the most directly comparable GAAP financial measure, as well as supplemental financial information with net sales expressed in constant currency. The Company has also provided a reconciliation of forward-looking Adjusted EBITDA and Adjusted EBITDA per diluted share to net income and net income per diluted share. This represents forward-looking information, and actual results may vary. Please see the risks and assumptions referred to in the Safe Harbor section of this press release.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

Safe Harbor

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, anticipated financial results, estimates and outlook (including as to net sales, Adjusted EBITDA, and Adjusted EBITDA per diluted share), plans, strategies, and objectives of management for 2024 and beyond or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to financial performance in the upcoming quarter, fiscal year 2024 and beyond. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to global economic conditions, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 29, 2023 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the impact of COVID-19; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; international conflicts, trade disputes and substantial dependence on demand from Asia; and the willingness of surgeons and patients to adopt a new or improved product and procedure.

We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections. Accordingly, investors should monitor such portions of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts.

Consolidated Balance Sheets (in 000's) Unaudited     ASSETS September 27, 2024 December 29, 2023 Current assets: Cash and cash equivalents

$

164,003

 

$

183,038

 

Investments available for sale

 

71,955

 

 

37,688

 

Accounts receivable trade, net

 

104,510

 

 

94,704

 

Inventories, net

 

40,361

 

 

35,130

 

Prepayments, deposits, and other current assets

 

16,277

 

 

14,709

 

Total current assets

 

397,106

 

 

365,269

 

Investments available for sale

 

-

 

 

11,703

 

Property, plant, and equipment, net

 

81,580

 

 

66,835

 

Finance lease right-of-use assets, net

 

73

 

 

183

 

Operating lease right-of-use assets, net

 

37,897

 

 

34,387

 

Goodwill

 

1,786

 

 

1,786

 

Deferred income taxes

 

5,324

 

 

5,190

 

Other assets

 

13,824

 

 

3,339

 

Total assets

$

537,590

 

$

488,692

 

  LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable

$

14,694

 

$

13,557

 

Obligations under finance leases

 

84

 

 

165

 

Obligations under operating leases

 

4,531

 

 

4,202

 

Allowance for sales returns

 

8,124

 

 

6,174

 

Other current liabilities

 

38,908

 

 

40,938

 

Total current liabilities

 

66,341

 

 

65,036

 

  Obligations under finance leases

 

-

 

 

42

 

Obligations under operating leases

 

35,385

 

 

31,425

 

Deferred income taxes

 

1,056

 

 

1,077

 

Asset retirement obligations

 

127

 

 

103

 

Pension liability

 

6,559

 

 

5,055

 

Total liabilities

 

109,468

 

 

102,738

 

  Stockholders' equity: Common stock

 

493

 

 

488

 

Additional paid-in capital

 

466,579

 

 

436,947

 

Accumulated other comprehensive loss

 

(5,602

)

 

(4,113

)

Accumulated deficit

 

(33,348

)

 

(47,368

)

Total stockholders' equity

 

428,122

 

 

385,954

 

Total liabilities and stockholders' equity

$

537,590

 

$

488,692

 

Consolidated Statements of Income (in 000's except for per share data) Unaudited     Three Months Ended Year to Date

% of

Sales

 

September 27,

2024

 

% of

Sales

 

September 29,

2023

 

Fav (Unfav)

Amount

 

%

 

% of

Sales

 

September 27,

2024

 

% of

Sales

 

September 29,

2023

 

Fav (Unfav)

Amount

 

%

Net sales

100.0%

$

88,590

100.0%

$

80,308

 

$

8,282

 

10.3%

100.0%

$

264,951

100.0%

$

246,142

 

$

18,809

 

7.6%

  Cost of sales

22.7%

 

20,103

 

20.8%

 

16,670

 

 

(3,433

)

(20.6)%

21.5%

 

57,017

 

22.0%

 

54,216

 

 

(2,801

)

(5.2)%

  Gross profit

77.3%

 

68,487

 

79.2%

 

63,638

 

 

4,849

 

7.6%

78.5%

 

207,934

 

78.0%

 

191,926

 

 

16,008

 

8.3%

  Selling, general and administrative expenses: General and administrative

24.4%

 

21,685

 

24.0%

 

19,266

 

 

(2,419

)

(12.6)%

25.9%

 

68,554

 

22.6%

 

55,461

 

 

(13,093

)

(23.6)%

Selling and marketing

30.1%

 

26,623

 

33.1%

 

26,607

 

 

(16

)

(0.1)%

31.0%

 

82,150

 

34.6%

 

85,238

 

 

3,088

 

3.6%

Research and development

16.4%

 

14,497

 

14.3%

 

11,470

 

 

(3,027

)

(26.4)%

15.8%

 

41,931

 

13.6%

 

33,535

 

 

(8,396

)

(25.0)%

Total selling, general, and administrative expenses

70.9%

 

62,805

 

71.4%

 

57,343

 

 

(5,462

)

(9.5)%

72.7%

 

192,635

 

70.8%

 

174,234

 

 

(18,401

)

(10.6)%

  Operating income

6.4%

 

5,682

 

7.8%

 

6,295

 

 

(613

)

(9.7)%

5.8%

 

15,299

 

7.2%

 

17,692

 

 

(2,393

)

(13.5)%

  Other income (expense): Interest income, net

1.6%

 

1,407

 

2.1%

 

1,690

 

 

(283

)

(16.7)%

1.6%

 

4,358

 

2.1%

 

5,287

 

 

(929

)

(17.6)%

Gain (loss) on foreign currency transactions

6.7%

 

5,931

 

-1.7%

 

(1,384

)

 

7,315

 

528.5%

0.2%

 

585

 

-1.3%

 

(3,240

)

 

3,825

 

118.1%

Royalty income

0.0%

 

-

 

0.1%

 

74

 

 

(74

)

(100.0)%

0.2%

 

508

 

0.0%

 

74

 

 

434

 

586.5%

Other income, net

0.2%

 

139

 

0.1%

 

71

 

 

68

 

95.8%

0.2%

 

532

 

0.1%

 

144

 

 

388

 

269.4%

Total other income, net

8.5%

 

7,477

 

0.6%

 

451

 

 

7,026

 

1557.9%

2.2%

 

5,983

 

0.9%

 

2,265

 

 

3,718

 

164.2%

  Income before provision for income taxes

14.9%

 

13,159

 

8.4%

 

6,746

 

 

6,413

 

95.1%

8.0%

 

21,282

 

8.1%

 

19,957

 

 

1,325

 

6.6%

  Provision for income taxes

3.6%

 

3,179

 

2.4%

 

1,929

 

 

(1,250

)

(64.8)%

2.7%

 

7,262

 

2.6%

 

6,366

 

 

(896

)

(14.1)%

  Net income

11.3%

 

9,980

 

6.0%

 

4,817

 

 

5,163

 

107.2%

5.3%

 

14,020

 

5.5%

 

13,591

 

 

429

 

3.2%

    Net income per share - basic

 

0.20

 

 

0.10

 

 

0.29

 

 

0.28

 

Net income per share - diluted

 

0.20

 

 

0.10

 

 

0.28

 

 

0.27

 

  Weighted average shares outstanding - basic

 

49,199

 

 

48,613

 

 

49,078

 

 

48,426

 

Weighted average shares outstanding - diluted

 

49,731

 

 

49,370

 

 

49,614

 

 

49,494

 

Consolidated Statements of Cash Flows (in 000's) Unaudited   Three Months Ended Year to Date

September 27,

2024

September 29,

2023

September 27,

2024

September 29,

2023

Cash flows from operating activities: Net income

$

9,980

 

$

4,817

 

$

14,020

 

$

13,591

 

Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation of property and equipment

 

1,757

 

 

1,345

 

 

4,516

 

 

3,743

 

Amortization of long-lived intangibles

 

-

 

 

(2

)

 

-

 

 

169

 

Accretion/Amortization of investments available for sale

 

(124

)

 

(348

)

 

(410

)

 

(2,172

)

Deferred income taxes

 

(13

)

 

(10

)

 

47

 

 

65

 

Change in net pension liability

 

(16

)

 

(139

)

 

(162

)

 

(766

)

Stock-based compensation expense

 

7,160

 

 

8,846

 

 

22,541

 

 

23,334

 

Change in asset retirement obligation

 

4

 

 

3

 

 

24

 

 

(104

)

Loss on disposal of property and equipment

 

1,642

 

 

17

 

 

1,668

 

 

41

 

Provision for sales returns and bad debts

 

868

 

 

921

 

 

1,947

 

 

1,925

 

Inventory provision

 

849

 

 

460

 

 

1,873

 

 

4,090

 

Changes in working capital: Accounts receivable

 

(10,139

)

 

(18,092

)

 

(9,703

)

 

(50,436

)

Inventories

 

(1,091

)

 

(5,593

)

 

(5,962

)

 

(9,975

)

Prepayments, deposits and other assets

 

(5,152

)

 

(919

)

 

(12,237

)

 

(3,584

)

Accounts payable

 

(5,649

)

 

(1,819

)

 

(2,031

)

 

(3,266

)

Other current liabilities

 

3,740

 

 

4,538

 

 

(1,048

)

 

5,970

 

Net cash provided by (used in) operating activities

 

3,816

 

 

(5,975

)

 

15,083

 

 

(17,375

)

  Cash flows from investing activities: Acquisition of property and equipment

 

(6,231

)

 

(9,185

)

 

(17,669

)

 

(15,100

)

Purchase of investments available for sale

 

(40,945

)

 

(9,712

)

 

(61,194

)

 

(52,314

)

Proceeds from sale or maturity of investments available for sale

 

11,935

 

 

50,737

 

 

39,141

 

 

119,359

 

Net provided by (used in) investing activities

 

(35,241

)

 

31,840

 

 

(39,722

)

 

51,945

 

  Cash flows from financing activities: Repayment of finance lease obligations

 

(42

)

 

(39

)

 

(124

)

 

(121

)

Repurchase of employee common stock for taxes withheld

 

-

 

 

(112

)

 

(1,396

)

 

(2,096

)

Proceeds from vested restricted stock and exercise of stock options

 

1,657

 

 

7,258

 

 

7,354

 

 

9,265

 

Net cash provided by financing activities

 

1,615

 

 

7,107

 

 

5,834

 

 

7,048

 

  Effect of exchange rate changes on cash and cash equivalents

 

1,037

 

 

(235

)

 

(230

)

 

(666

)

  Increase (decrease) in cash and cash equivalents

 

(28,773

)

 

32,737

 

 

(19,035

)

 

40,952

 

Cash and cash equivalents, at beginning of the period

 

192,776

 

 

94,695

 

 

183,038

 

 

86,480

 

Cash and cash equivalents, at end of the period

$

164,003

 

$

127,432

 

$

164,003

 

$

127,432

 

Reconciliation of Non-GAAP Financial Measure Net Income to Adjusted EBITDA (in 000's except for per share data) Unaudited  

2021

 

Q1-22

 

Q2-22

 

Q3-22

 

Q4-22

 

2022

 

Q1-23

 

Q2-23

 

Q3-23

 

Q4-23

 

2023

 

Q1-24

 

Q2-24

 

Q3-24

 

2024

Outlook(2)

Net income (loss) - (as reported)

$

27,511

 

$

9,602

 

$

13,038

 

$

10,262

 

$

6,763

 

$

39,665

 

$

2,710

 

$

6,064

 

$

4,817

 

$

7,756

 

$

21,347

 

$

(3,339

)

$

7,379

 

$

9,980

 

$

3,800

 

Provision (benefit) for income taxes

 

3,793

 

 

1,925

 

 

2,431

 

 

2,315

 

 

(784

)

 

5,887

 

 

2,009

 

 

2,428

 

 

1,929

 

 

5,983

 

 

12,349

 

 

1,128

 

 

2,955

 

 

3,179

 

 

7,600

 

Other (income) expense, net

 

2,035

 

 

586

 

 

1,551

 

 

1,128

 

 

(5,015

)

 

(1,750

)

 

(1,919

)

 

105

 

 

(451

)

 

(3,334

)

 

(5,599

)

 

(70

)

 

1,564

 

 

(7,477

)

 

(7,500

)

Depreciation

 

3,608

 

 

994

 

 

1,030

 

 

1,077

 

 

1,380

 

 

4,481

 

 

1,113

 

 

1,285

 

 

1,345

 

 

1,368

 

 

5,111

 

 

1,237

 

 

1,522

 

 

1,757

 

 

6,000

 

(Gain) loss on disposal of property plant and equipment(3)

 

2

 

 

-

 

 

-

 

 

-

 

 

65

 

 

65

 

 

-

 

 

24

 

 

17

 

 

32

 

 

73

 

 

-

 

 

26

 

 

1,642

 

 

1,700

 

Amortization of intangible assets

 

34

 

 

8

 

 

7

 

 

7

 

 

6

 

 

28

 

 

7

 

 

10

 

 

(2

)

 

(2

)

 

13

 

 

-

 

 

-

 

 

-

 

 

-

 

Stock-based compensation

 

14,605

 

 

3,894

 

 

5,754

 

 

5,727

 

 

4,996

 

 

20,371

 

 

6,065

 

 

8,423

 

 

8,846

 

 

182

 

 

23,516

 

 

6,339

 

 

9,042

 

 

7,160

 

 

30,200

 

Adjusted EBITDA

$

51,588

 

$

17,009

 

$

23,811

 

$

20,516

 

$

7,411

 

$

68,747

 

$

9,985

 

$

18,339

 

$

16,501

 

$

11,985

 

$

56,810

 

$

5,295

 

$

22,488

 

$

16,241

 

$

41,800

 

Adjusted EBITDA as a % of Revenue

 

22.4

%

 

26.9

%

 

29.4

%

 

27.0

%

 

11.6

%

 

24.2

%

 

13.6

%

 

19.9

%

 

20.6

%

 

15.7

%

 

17.6

%

 

6.8

%

 

22.7

%

 

18.3

%

 

12.2

%

  Net income (loss) per share, diluted - (as reported)

$

0.56

 

$

0.19

 

$

0.26

 

$

0.21

 

$

0.14

 

$

0.80

 

$

0.05

 

$

0.12

 

$

0.10

 

$

0.16

 

$

0.43

 

$

(0.07

)

$

0.15

 

$

0.20

 

$

0.07

 

Provision (benefit) for income taxes

 

0.08

 

 

0.04

 

 

0.05

 

 

0.05

 

 

(0.02

)

 

0.12

 

 

0.04

 

 

0.05

 

 

0.04

 

 

0.12

 

 

0.25

 

 

0.02

 

 

0.06

 

 

0.06

 

 

0.15

 

Other (income) expense, net

 

0.04

 

 

0.01

 

 

0.03

 

 

0.02

 

 

(0.10

)

 

(0.04

)

 

(0.04

)

 

-

 

 

(0.01

)

 

(0.07

)

 

(0.11

)

 

-

 

 

0.03

 

 

(0.15

)

 

(0.14

)

Depreciation

 

0.07

 

 

0.02

 

 

0.02

 

 

0.02

 

 

0.03

 

 

0.09

 

 

0.02

 

 

0.03

 

 

0.03

 

 

0.03

 

 

0.10

 

 

0.03

 

 

0.03

 

 

0.04

 

 

0.12

 

(Gain) loss on disposal of property plant and equipment

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

0.03

 

 

0.03

 

Amortization of intangible assets

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

Stock-based compensation

 

0.30

 

 

0.08

 

 

0.12

 

 

0.12

 

 

0.10

 

 

0.41

 

 

0.12

 

 

0.17

 

 

0.18

 

 

-

 

 

0.48

 

 

0.13

 

 

0.18

 

 

0.14

 

 

0.58

 

Adjusted EBITDA per share, diluted(1)

$

1.04

 

$

0.35

 

$

0.48

 

$

0.41

 

$

0.15

 

$

1.39

 

$

0.20

 

$

0.37

 

$

0.33

 

$

0.24

 

$

1.15

 

$

0.11

 

$

0.45

 

$

0.33

 

$

0.80

 

  Weighted average shares outstanding - Diluted

 

49,456

 

 

49,288

 

 

49,223

 

 

49,549

 

 

49,389

 

 

49,380

 

 

49,500

 

 

49,516

 

 

49,370

 

 

49,242

 

 

49,427

 

 

48,907

 

 

49,811

 

 

49,731

 

 

52,000

 

  (1) Adjusted EBITDA per diluted share may not add due to rounding (2) 2024 Adjusted EBITDA Outlook line items are all approximations and assumes breakeven Net Income (3) The Q3-2024 non cash write-off of $1.6M was related to the former EVO Experience Center ICL Sales by Geography (in 000's) Unaudited Fiscal Year Three Months Ended ICL Sales by Region(5)

2021

2022

2023

June 30,

2023

September 29,

2023

December 29,

2023

March 29,

2024

June 28,

2024

September 27,

2024

  Americas(1)

$

14,054

 

$

20,114

 

$

22,233

 

$

5,954

 

$

5,449

 

$

5,264

 

$

6,260

 

$

6,794

 

$

6,187

 

  EMEA(2)

 

37,343

 

 

36,715

 

 

39,318

 

 

9,782

 

 

9,253

 

 

10,103

 

 

11,299

 

 

10,727

 

 

10,333

 

  APAC(3)

 

161,508

 

 

212,883

 

 

257,876

 

 

77,376

 

 

66,367

 

 

59,254

 

 

59,592

 

 

81,844

 

 

72,581

 

  Global ICL Sales

$

212,905

 

$

269,712

 

$

319,427

 

$

93,112

 

$

81,069

 

$

74,621

 

$

77,151

 

$

99,365

 

$

89,101

 

  Global ICL Sales Growth

 

51

%

 

27

%

 

18

%

 

19

%

 

13

%

 

22

%

 

9

%

 

7

%

 

10

%

  Americas ICL Sales Growth

 

59

%

 

43

%

 

11

%

 

12

%

 

5

%

 

(8

)%

 

12

%

 

14

%

 

14

%

  EMEA ICL Sales Growth

 

45

%

 

(2

)%

 

7

%

 

(11

)%

 

14

%

 

18

%

 

11

%

 

10

%

 

12

%

  APAC ICL Sales Growth

 

51

%

 

32

%

 

21

%

 

26

%

 

13

%

 

26

%

 

9

%

 

6

%

 

9

%

  Global ICL Unit Growth

 

48

%

 

33

%

 

19

%

 

21

%

 

14

%

 

19

%

 

2

%

 

3

%

 

6

%

  Fiscal Year Three Months Ended ICL Sales by Country(4)(5)

2021

2022

2023

June 30,

2023

September 29,

2023

December 29,

2023

March 29,

2024

June 28,

2024

September 27,

2024

  China

$

107,130

 

$

147,967

 

$

185,404

 

$

61,288

 

$

48,262

 

$

40,813

 

$

38,460

 

$

63,345

 

$

51,719

 

Growth

 

50

%

 

38

%

 

25

%

 

33

%

 

14

%

 

30

%

 

10

%

 

3

%

 

7

%

  Japan

$

28,688

 

$

32,623

 

$

36,352

 

$

8,563

 

$

9,091

 

$

9,495

 

$

10,227

 

$

9,735

 

$

10,490

 

Growth

 

56

%

 

14

%

 

11

%

 

13

%

 

12

%

 

16

%

 

11

%

 

14

%

 

15

%

  South Korea

$

15,173

 

$

17,940

 

$

19,853

 

$

3,316

 

$

4,886

 

$

4,996

 

$

6,725

 

$

3,973

 

$

5,434

 

Growth

 

36

%

 

18

%

 

11

%

 

(15

)%

 

1

%

 

39

%

 

1

%

 

20

%

 

11

%

  United States

$

9,478

 

$

15,070

 

$

17,168

 

$

4,446

 

$

4,162

 

$

4,164

 

$

5,039

 

$

5,541

 

$

4,823

 

Growth

 

58

%

 

59

%

 

14

%

 

10

%

 

6

%

 

(8

)%

 

15

%

 

25

%

 

16

%

  Notes: (1) Americas includes the United States, Canada and Latin American countries (2) EMEA includes Spain, Germany, United Kingdom, European, Middle East and Africa Distributors (3) APAC includes China, Japan, South Korea, India and the rest of Asia Pacific distributors (4) ICL Sales by country includes countries representing more than 5% of total ICL sales in the most recently completed fiscal year (5) ICL sales do not include IOL, injector or other sales Reconciliation of Non-GAAP Financial Measure Constant Currency Sales (in 000's) Unaudited     Three Months Ended As Reported Constant Currency Sales

September 27,

2024

Effect of

Currency

Constant

Currency

September 29,

2023

$ Change

% Change

$ Change

% Change

ICL

$

89,101

 

$

300

 

$

89,401

 

$

81,069

 

$

8,032

 

9.9

%

$

8,332

 

10.3

%

Cataract IOL

 

-

 

 

-

 

 

-

 

 

(221

)

 

221

 

(100.0

)%

 

221

 

(100.0

)%

Other

 

(511

)

 

(2

)

 

(513

)

 

(540

)

 

29

 

(5.4

)%

 

27

 

(5.0

)%

Total Sales

$

88,590

 

$

298

 

$

88,888

 

$

80,308

 

$

8,282

 

10.3

%

$

8,580

 

10.7

%

    Year to Date As Reported Constant Currency Sales

September 27,

2024

Effect of

Currency

Constant

Currency

September 29,

2023

$ Change

% Change

$ Change

% Change

ICL

$

265,617

 

$

2,515

 

$

268,132

 

$

244,806

 

$

20,811

 

8.5

%

$

23,326

 

9.5

%

Cataract IOL

 

-

 

 

-

 

 

-

 

 

1,295

 

 

(1,295

)

(100.0

)%

 

(1,295

)

(100.0

)%

Other

 

(666

)

 

111

 

 

(555

)

 

41

 

 

(707

)

(1724.4

)%

 

(596

)

(1453.7

)%

Total Sales

$

264,951

 

$

2,626

 

$

267,577

 

$

246,142

 

$

18,809

 

7.6

%

$

21,435

 

8.7

%

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241030604379/en/

Investors & Media Brian Moore Vice President, Investor Relations and Corporate Development 626-303-7902, Ext. 3023 bmoore@staar.com

Investors – Asia Niko Liu, CFA Director, Investor Relations and Corporate Development – Asia +852-6092-5076 nliu@staar.com